FOXP3 and central nervous system cancer: In 2008, Heimberger et al. [11] for the first time analyzed prognostic impact of Foxp3+ TILs in human glioma based on immunohistochemical staining and reached no statistical significance between 25 patients with Foxp3 presence and 27 ones with Foxp3 absence.